SCHEMBL6042452

SCHEMBL6042452

Cc1c(Br)ccc2ccc(Br)cc12

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TYMS P04818 2/20 0.41
CYP2A6 P11509 1/20 0.39
HSP90AA1 P07900 1/20 0.38
TLR9 Q9NR96 1/20 0.38
ALDH1A1 P00352 4/20 0.37
KDM4E B2RXH2 1/20 0.37
MEN1 O00255 1/20 0.37
MAPT P10636 1/20 0.37
KMT2A Q03164 1/20 0.37
EPRS1 P07814 1/20 0.36
LMNA P02545 1/20 0.36
HPGD P15428 1/20 0.36
PLG P00747 1/20 0.36
PLAU P00749 1/20 0.36
PLAT P00750 1/20 0.36
MAPK1 P28482 2/20 0.35
CYP1A2 P05177 1/20 0.35
CYP2D6 P10635 1/20 0.35
CYP2C9 P11712 1/20 0.35
CYP2C19 P33261 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6042829 0.84 CYP2A6 (0.43) CYP2A6HSP90AA1TLR9ALDH1A1KDM4E
SCHEMBL8370910 0.82 CYP2A6 (0.52) TYMSCYP2A6ALDH1A1KDM4EMEN1
SCHEMBL21122871 0.82 CYP1A2 (0.48) TYMSCYP2A6ALDH1A1KDM4ELMNA
SCHEMBL38662570 0.81 CYP2A6 (0.42) TYMSCYP2A6ALDH1A1KDM4EMEN1
SCHEMBL29595200 0.77 CYP2A6 (0.52) TYMSCYP2A6ALDH1A1KDM4EMEN1
SCHEMBL1569370 0.77 CYP2A6 (0.52) TYMSCYP2A6ALDH1A1KDM4EMEN1
SCHEMBL28395213 0.76 CYP2A6 (0.42) TYMSCYP2A6HSP90AA1TLR9ALDH1A1
SCHEMBL1941906 0.74 CYP2A6 (0.60) CYP2A6ALDH1A1MAPTHPGDMAPK1
SCHEMBL30266173 0.74 CYP2A6 (0.60) CYP2A6ALDH1A1MAPTHPGDMAPK1
SCHEMBL17281129 0.74 CYP2A6 (0.50) TYMSCYP2A6ALDH1A1KDM4EMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1256326-C Novel 4- (oxoxyphenyl) -3-oxopiperidines for the treatment of cardiac and renal insufficiency HOFFMANN LA ROCHE (CH) 2006-05-17 CN disclosed
US-20060079533-A1 Methods of treating alzheimer's disease NIEMAN JAMES A 2006-04-13 US disclosed
US-6150526-A Piperidine derivative having renin inhibiting activity HOFFMANN-LA ROCHE INC. (US) 2000-11-21 US disclosed
US-6051712-A PREVENTION OF HIGH BLOOD PRESSURE AND CARDIAC INSUFFICIENCY, AS WELL AS GLAUCOMA, CARDIAC INFARCT, KIDNEY INSUFFICIENCY AND RESTENOSIS HOFFMANN-LA ROCHE INC. (US) 2000-04-18 US disclosed
CN-1202152-A Novel 4- (oxoxyphenyl) -3-oxopiperidines for the treatment of cardiac and renal insufficiency HOFFMANN LA ROCHE (CH) 1998-12-16 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060079533-A1 Methods of treating alzheimer's disease BACE1, PSEN1, PSEN2 TYMS 2259/4885CYP2A6 3577/4885HSP90AA1 2364/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.